Qiagen N.V.

QIAGEN and EQT Private Equity announce agreement on a recommended voluntary all-cash public takeover offer

QIAGEN and EQT Private Equity agreed on an all-cash voluntary public takeover offer for all outstanding QIAGEN shares at €46.50 per share. The price represents a 40.3% premium to the unaffected €33.15 XETRA close and values QIAGEN at approximately €10.8 billion in enterprise value (~$12.1 billion including ~$1.1 billion of net debt). QIAGEN's boards unanimously recommend acceptance. Closing is expected in mid-2027, subject to a 50%-plus-one minimum acceptance threshold, EGM approval of post-closing measures at 80% of votes cast, and merger control and foreign investment clearances. On completion, QIAGEN's NYSE and Frankfurt listings will be terminated and remaining shareholders will receive cash equal to the offer price less withholding taxes; EQT is joined by co-investors ADIA and CPP Investments with committed financing and no financing condition.

•18d ago

QIAGEN Expands AI-Powered Bioinformatics for Research and Drug Discovery

QIAGEN launched IPA Investigator, an AI research companion for its Ingenuity Pathway Analysis tool that lets researchers query biological data in natural language while exposing the underlying evidence. It also introduced the QIAGEN Discovery Platform, extending AI into automated drug-discovery workflows for target identification, biomarker discovery, and hypothesis generation. The launches build on QIAGEN Digital Insights' 25-year knowledge base used by roughly 150,000 researchers, positioning QGEN against a market projected to grow from about $12 billion in 2026 to more than $25 billion by 2031.

•1mo ago

QIAGEN Completes U.S. QIAstat-Dx Bloodstream Infection Portfolio With FDA Clearance of New Bacteria Detection Panel

QIAGEN received FDA clearance for its QIAstat-Dx BCID GN Plus AMR Panel, completing the U.S. QIAstat-Dx bloodstream infection portfolio. The new panel detects 13 gram-negative bacterial targets and 18 antibiotic resistance markers in about one hour, complementing the recently cleared gram-positive/fungal panel; together they cover 33 pathogen targets and 28 resistance markers. The clearance expands QIAstat-Dx's U.S. infectious disease menu on a platform with more than 5,200 cumulative placements, supporting growth in syndromic testing revenue.

•1mo ago

QIAGEN Launches QIAmini to Automate Small-Batch Sample Preparation

QIAGEN launched QIAmini, a compact benchtop system that automates DNA and RNA extraction for research labs processing small sample batches, cutting hands-on time by over 80% versus manual processing. QIAGEN sizes the addressable market at more than 100,000 potential instrument placements worldwide, and QIAmini is the company's third new sample preparation system launched in 2026. Five dedicated kits support tissue, blood, swabs and other biological materials for PCR, digital PCR and NGS workflows; the system is research-use only.

•1mo ago

QIAGEN Launches QIAsymphony Connect for Automated Clinical Nucleic Acid Extraction

QIAGEN announced the commercial launch of QIAsymphony Connect, an IVD-compliant automation platform for nucleic acid extraction designed to standardize clinical workflows. The system builds on the existing QIAsymphony installed base of over 3,300 units and maintains backward compatibility with current reagent kits to facilitate migration. Regulatory listings are complete with the FDA and EUDAMED, and the company has received initial customer orders as it targets high-growth applications like liquid biopsy.

•2mo ago

QIAGEN Receives U.S. FDA Clearance for First QIAstat-Dx Bloodstream Infection Panel

QIAGEN received FDA clearance for the QIAstat-Dx BCID GPF Plus AMR Panel, marking its entry into the U.S. bloodstream infection testing market. The panel detects 20 pathogen targets and 10 antimicrobial resistance markers from positive blood cultures in about one hour, supporting faster treatment decisions. This clearance expands the QIAstat-Dx platform's coverage to four major infectious disease areas, with a complementary gram-negative panel currently under FDA review.

•2mo ago

QIAGEN Exceeds Q2 2026 Outlook as Pillars Deliver Solid Sales Growth; Reaffirms Full-Year Outlook

QIAGEN reported Q2 2026 net sales of $535 million, flat year-over-year but exceeding the outlook for a 2% CER decline, with adjusted diluted EPS of $0.62 topping the $0.60 outlook. Growth pillars delivered 5% CER growth driven by Sample technologies and QIAcuity, while QuantiFERON sales managed a slight increase despite lower U.S. immigration testing demand. The company reaffirmed its full-year 2026 outlook for 1-2% CER sales growth and adjusted EPS of at least $2.43 CER, and announced a 40% increase to the 2026 dividend.

•3mo ago

QIAGEN Highlights Molecular Testing Solutions Supporting Response to Growing U.S. Cyclospora Outbreak

QIAGEN highlighted its portfolio of molecular testing solutions in response to a growing outbreak of cyclosporiasis in the U.S., which has seen over 1,600 confirmed cases since May 2026. The company noted that its FDA-cleared QIAstat-Dx Gastrointestinal Panel 2 can detect the Cyclospora parasite in about an hour, while its QIAcuity and QIAseq tools support public health investigations. Management emphasized that the rise in cases underscores the need for rapid detection to support timely patient care and effective public health responses.

•3mo ago

QIAGEN Expands QIAstat-Dx Bloodstream Infection Testing Menu in Europe

QIAGEN launched the CE-IVDR-certified QIAstat-Dx BCID GN Plus AMR Panel in Europe, expanding its bloodstream infection testing menu. The new panel detects 13 gram-negative pathogen targets and 18 antimicrobial resistance markers in about one hour, complementing the existing gram-positive panel for comprehensive coverage. Regulatory review by the FDA is underway for the U.S. market, while the global installed base of QIAstat-Dx systems exceeded 5,200 instruments at the end of 2025.

•3mo ago